Full Text
The Clinical and Cost Effectiveness of Dasatinib Versus Nilotinib for The First and Second Line Treatment of People with Chronic Myeloid Leukaemia

Abstract

Authors

T Ward B Jones JP Harrison M Hurst D Tyas P McEwan J Gordon

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×